The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and ...

AbbVie is joining the chase for new obesity drugs, but rather than getting a me-too GLP-1 drug, the pharmaceutical giant is landing rights to a clinical-stage molecule that goes after two novel ...

CagriSema is a combination of cagrilintide — a nascent form of weight loss treatment known as an amylin analog — and ...

including the unimolecular GLP-1 and amylin receptor agonist amycretin and next-gen subcutaneous obesity treatment candidate, CagriSema. NVO is also evaluating several other obesity drugs across ...

With reference to Gubra's A/S (CPSE:GUBRA) announcement on March 28, 2025 regarding the satisfaction of the regulatory condition for a license agreement to develop GUB014295, a potential ...

Petrelintide is part of an emerging class of drugs that bind to and activate the amylin receptor. The once-weekly injectable Zealand drug is a peptide engineered to be a long-acting version of ...

Before Roche, U.S. AbbVie also announced its entry into the obesity drug market using amylin analogs on the 4th. The company has signed a license agreement for the obesity drug candidate ...

Roche is in-licensing co-development and co-commercialization rights to Denmark’s Zealand Pharma’s long-acting amylin analog, petrelintide, being developed in phase IIb studies for people who ...

Abbvie Inc. is buying into the obesity fray in a potential $1.875 billion development and commercialization agreement with Danish peptide drug discovery specialist ... long-acting analog of the ...

Amylin drugs work similarly to the popular GLP-1 drugs ruling the obesity space. The GLP-1 space is dominated by NVO and Eli Lilly LLY, with their popular obesity injections, Wegovy (semaglutide) and ...